Blue Jet Healthcare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹376 Cr +127.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
BJ

Blue Jet Healthcare Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Blue Jet Healthcare Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹235Cr
−30.9% YoY
+22.4% QoQ
Net profit
₹64Cr
−41.8% YoY
+60% QoQ
Margin
30%
−11 pp YoY
+6 pp QoQ
Price₹596
Market cap₹11.1K Cr
P/E47.1

The short version

PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27. Blue Jet Healthcare expects growth driven by improved order visibility in Pharmaceutical Intermediates (PI) and Contrast Media (CM) segments in FY27.

From Blue Jet Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27.
  • Contrast media business forecasted to deliver double-digit growth in FY27 supported by volume growth and new product launches (both iodinated and gadolinium types).
  • Inventory destocking in PI segment completed, leading to improved order visibility and confidence in surpassing previous peak sales of FY25.
  • Two high-conviction lateral entry opportunities being planned with dedicated capacity at Vizag, expected to scale in 24-30 months.
  • Peptide building blocks for GLP-1 programs progressing with pilot/lab supplies started; peptide end product stage in early phases.
  • Artificial sweetener product under validation; commercial volumes expected post-Vizag facility commissioning.

2 more points from Blue Jet Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Vizag Greenfield Project: Planned total capex of approximately INR 1,000 crores over about 3 years. Phase 1 to develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates.
  • Mahad Unit 3 Backward Integration Project: Final stages of completion; expected to start production in H2 FY27. Focused on key raw material for contrast media to strengthen supply chain and resilience.
  • Other Additions: Capex of approximately INR 400 crores proposed in FY27 for Vizag, Mahad completion, and Ambernath expansions.

2 more points from Blue Jet Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has confirmed having orders in hand, especially in the pharma intermediates (PI) segment, with destocking largely completed and shipments rolling out. (Page 16)
  • Subsequent to supply chain realignment, additional orders have been secured in the PI segment, boosting confidence in near-term volumes. (Page 14)
  • For contrast media, the increase in revenue to INR190 crores in Q4 belongs entirely to the order book for that quarter, with normalized goods in transit. (Page 14)

2 more points from Blue Jet Healthcare Ltd's call on order book

Create a free account to keep reading this call

Blue Jet Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Blue Jet Healthcare Ltd Q4 FY26 results — key figures

Blue Jet Healthcare Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue235340-30.9%192+22.4%
Operating profit (EBITDA)71140-49.3%47+51.1%
Operating margin30%41%-11 pp24%+6 pp
Profit before tax87147-40.8%54+61.1%
Net profit (PAT)64110-41.8%40+60%
EPS (₹)3.716.35-41.6%2.32+59.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Blue Jet Healthcare Ltd Q4 FY26 results?

PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27. Blue Jet Healthcare expects growth driven by improved order visibility in Pharmaceutical Intermediates (PI) and Contrast Media (CM) segments in FY27.

What is Blue Jet Healthcare Ltd share price analysis?

Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.

Is Blue Jet Healthcare Ltd planning capital expenditure?

Vizag Greenfield Project: Planned total capex of approximately INR 1,000 crores over about 3 years.

Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.